Measurement of serotonin transporter binding with PET and [11C]MADAM: A test–retest reproducibility study

[11C]MADAM, or [11C]N,N‐dimethyl‐2‐(2‐amino‐4‐methylphenyl thio)benzylamine, is a radioligand suitable for positron emission tomography (PET) studies of the serotonin transporter (5‐HTT) in man. The purpose of this study was to examine the test–retest reproducibility using a design tailored for future applied studies. Nine healthy male subjects were examined with PET and [11C]MADAM under baseline conditions at two occasions 4–8 weeks apart. The subjects participated in a Phase 1 trial to which the present study was an addendum. Eight regions of interest were studied, including frontal cortex, hippocampal complex, and the raphe nuclei. All regions, but the raphe nuclei, were defined on MR‐images to which the PET‐images were coregistered using SPM2. Binding potentials were calculated using the simplified reference tissue model, with cerebellum as reference region. Test–retest data were calculated from the binding potentials, and included binding potential (BP) quotient, BP difference, and the intraclass correlation coefficient. The quotient was about one in all regions, and the mean difference varied between 0 and 11%. The intraclass correlation coefficient varied between 0.96 and 0.51 in the raphe nuclei and averaged bilateral regions. [11C]MADAM was shown to have good to excellent reliability in measurements of 5‐HTT binding in brain regions of interest in research on psychiatric disorders. Synapse 60:256–263, 2006. © 2006 Wiley‐Liss, Inc.

[1]  J. Marcusson,et al.  High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue , 1989, Brain Research.

[2]  M Slifstein,et al.  Validation and Reproducibility of Measurement of 5-HT1A Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  Sylvain Houle,et al.  Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. , 2004, The American journal of psychiatry.

[4]  C. Halldin,et al.  Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Denis Guilloteau,et al.  Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter , 2001 .

[6]  A Frazer,et al.  Effects of Chronic Antidepressant Treatments on Serotonin Transporter Function, Density, and mRNA Level , 1999, The Journal of Neuroscience.

[7]  Alan A. Wilson,et al.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. , 2001, The American journal of psychiatry.

[8]  J. Hirvonen,et al.  Measurement of Cortical Dopamine D1 Receptor Binding with [11C]SCH 23390: A Test–Retest Analysis , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  K. Fite,et al.  Diurnal variation in serotonin immunoreactivity in the dorsal raphe nucleus , 2005, Brain Research.

[10]  S. Horschitz,et al.  Down-regulation of the rat serotonin transporter upon exposure to a selective serotonin reuptake inhibitor , 2001, Neuroreport.

[11]  Sylvain Houle,et al.  In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. , 2002, Nuclear medicine and biology.

[12]  Marc Laruelle,et al.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.

[13]  J. Palacios,et al.  Autoradiography of antidepressant binding sites in the human brain: localization using [3h]imipramine and [3h]paroxetine , 1988, Neuroscience.

[14]  Denis Guilloteau,et al.  [11C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET , 2005, Synapse.

[15]  C. Halldin,et al.  Selectivity of 3H‐MADAM binding to 5‐hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects , 2004, British journal of pharmacology.

[16]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[17]  A. Heinz,et al.  DASB –in vitro binding characteristics on human recombinant monoamine transporters with regard to its potential as positron emission tomography (PET) tracer , 2004, Journal of neurochemistry.

[18]  J. Hirvonen,et al.  Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride , 2003, Nuclear medicine communications.

[19]  Alan A. Wilson,et al.  Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  S. Laughlin,et al.  An Energy Budget for Signaling in the Grey Matter of the Brain , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  Denis Guilloteau,et al.  Pharmacological Characterization ofN,N-Dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a Ligand of the Serotonin Transporter with High Affinity and Selectivity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[22]  C. Halldin,et al.  Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain , 2003, Psychopharmacology.

[23]  G. Halliday,et al.  Cytoarchitecture of the human dorsal raphe nucleus , 1990, The Journal of comparative neurology.

[24]  W. Abramowitz,et al.  Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover study. , 2000, Clinical therapeutics.

[25]  G. Sedvall,et al.  Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. , 1988, Archives of general psychiatry.

[26]  L. Farde,et al.  PET analysis of central [11 C]raclopride binding in healthy young adults and schizophrenic patients—reliability and age effects , 1992 .

[27]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[28]  K Wienhard,et al.  The ECAT EXACT HR: Performance of a New High Resolution Positron Scanner , 1994, Journal of computer assisted tomography.

[29]  T. Greitz,et al.  Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. , 1981, Journal of computer assisted tomography.

[30]  Sylvain Houle,et al.  Effects of Tryptophan Depletion on the Serotonin Transporter in Healthy Humans , 2005, Biological Psychiatry.

[31]  N. Rojansky,et al.  Influence of age, sex and diurnal variability on imipramine receptor binding and serotonin uptake in platelets of normal subjects. , 1991, Journal of psychiatric research.

[32]  Guy Marchal,et al.  Automated multi-moda lity image registration based on information theory , 1995 .